Zacks Investment Research downgraded Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to Hold in a report released today.
- Updated: November 27, 2016
Just yesterday Conatus Pharmaceuticals Inc (NASDAQ:CNAT) traded 2.12% higher at $1.96. Conatus Pharmaceuticals Inc’s 50-day moving average is $1.86 and its 200-day moving average is $2.03. The last stock price is down -4.75% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 59,269 shares of CNAT traded hands, down from an average trading volume of 562,661
Zacks Investment Research has downgraded Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to Hold in a report released on 11/22/2016.
Previously on 11/18/2016, Zacks Investment Research released a statement about Conatus Pharmaceuticals Inc (NASDAQ:CNAT) increased the target price from $0.00 to $2.25. At the time, this indicated a possible upside of 0.15%.
Recent Performance Chart
Conatus Pharmaceuticals Inc has 52 week low of $1.40 and a 52 week high of $4.05 and has a market capitalization of $0.
Brief Synopsis On Conatus Pharmaceuticals Inc (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.